Transaction in Own Shares | 30-Jul-2025 | 07:05 | RNS |
2nd Quarter Results | 30-Jul-2025 | 07:00 | RNS |
Transaction in Own Shares | 29-Jul-2025 | 07:00 | RNS |
GSK enters Hengrui Pharma collaboration agreements | 28-Jul-2025 | 07:00 | RNS |
Transaction in Own Shares | 28-Jul-2025 | 07:00 | RNS |
Transaction in Own Shares | 25-Jul-2025 | 07:00 | RNS |
Blenrep approved in the EU for multiple myeloma | 24-Jul-2025 | 17:00 | RNS |
Transaction in Own Shares | 24-Jul-2025 | 07:00 | RNS |
US FDA review extended for Blenrep | 23-Jul-2025 | 17:00 | RNS |
Transaction in Own Shares | 23-Jul-2025 | 07:00 | RNS |
Transaction in Own Shares | 22-Jul-2025 | 07:00 | RNS |
Transaction in Own Shares | 21-Jul-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 18-Jul-2025 | 15:30 | RNS |
Transaction in Own Shares | 18-Jul-2025 | 07:00 | RNS |
Blenrep US ODAC outcome | 18-Jul-2025 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 1,462.50p |
Change Today | 65.50p |
% Change | 4.69 % |
52 Week High | 1,671.00 |
52 Week Low | 1,264.00 |
Volume | 11,473,020 |
Shares Issued | 4,079.10m |
Market Cap | £59,657m |
Beta | 0.00 |
RiskGrade | 129 |
Value | ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 2 |
Neutral | 15 |
Sell | 3 |
Strong Sell | 0 |
Total | 23 |
Latest | Previous | |
---|---|---|
Q2 | Q1 | |
Ex-Div | 14-Aug-25 | 15-May-25 |
Paid | 09-Oct-25 | 10-Jul-25 |
Amount | 16.00p | 16.00p |
Time | Volume / Share Price |
17:45 | 7,700 @ 1,462.24p |
15:59 | 5 @ 1,455.50p |
16:16 | 1 @ 1,459.50p |
15:52 | 5 @ 1,454.00p |
15:52 | 4 @ 1,454.00p |
You are here: research